共 50 条
- [41] A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Chakrabarti, TurjaAllen, Greg M.Gubens, Matthew A.Mulvey, ClaireManana, Ana I. VelazquezWu, WeiGee, MeganTan, LisaBivona, Trever G.Blakely, Collin M.
- [42] Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyCANCER CELL, 2021, 39 (09) : 1279 - +Zhou, QingXu, Chong-RuiCheng, YingLiu, Yun-PengChen, Gong-YanCui, Jiu-WeiYang, NongSong, YongLi, Xiao-LingLu, ShunZhou, Jian-YingMa, Zhi-YongYu, Shi-YingHuang, ChengShu, Yong-QianWang, ZhenYang, Jin-JiTu, Hai-YanZhong, Wen-ZhaoWu, Yi-Long
- [43] Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (02):Yang, James Chih-HsinReckamp, Karen L.Kim, Young-ChulNovello, SilviaSmit, Egbert F.Lee, Jong-SeokSu, Wu -ChouAkerley, Wallace L.Blakely, Collin M.Groen, Harry J. M.Bazhenova, LyudmilaCosta, Enric CarcerenyChiari, RitaHsia, Te-ChunGolsorkhi, TonyDespain, DarrinShih, DannyPopat, SanjayWakelee, Heather
- [44] Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expressionANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379Iwata, HirojiKrop, Ian E.Masuda, NorikazuMukohara, ToruTakahashi, ShunjiNakayama, TakahiroInoue, KenichiToyama, TatsuyaYamamoto, YutakaAlvarez, Ricardo H.Takahashi, MasatoOsaki, AkihikoOhwada, ShoichiMostillo, JosephTanaka, YoshimiSternberg, DavidSellami, Dalila
- [45] An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLCOncogene, 2019, 38 : 1398 - 1409Kimio YonesakaNaoki TakegawaSatomi WatanabeKoji HarataniHisato KawakamiKazuko SakaiYasutaka ChibaNaoyuki MaedaTakashi KagariKenji HirotaniKazuto NishioKazuhiko Nakagawa
- [46] CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLCANNALS OF ONCOLOGY, 2019, 30Zhou, Q.Wu, Y-L.Cheng, Y.Liu, Y.Chen, G.Cui, J.Yang, N.Song, Y.Li, X-L.Lu, S.Zhou, J.Ma, Z.Yu, S-Y.Huang, C.Shu, Y.
- [47] Single agent activity of U3-1402, a HER3-argeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Kogawa, TakahiroYonemori, KanMasuda, NorikazuTakahashi, ShunjiTakahashi, MasatoIwase, HirotakaNakayama, TakahiroSaeki, ToshiakiToyama, TatsuyaTakano, ToshimiOnuma, HiroshiOgawa, HayaoTanaka, YoshimiIgari, YoshikoSugihara, MasahiroVigliotti, MicheleYu, ChanningOlivo, Martin SebastianUeno, SuguruIwata, Hiroji
- [49] SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLCJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S429Zhou, Q.Li, J.Wang, J.Yang, L.Fang, J.Dong, X.Yi, T.Min, X.Xu, F.Chen, J.Zhong, D.Bai, J.Liu, L.Zeng, A.Tang, J.Wu, H.Luo, X.Yu, J.Su, W.Wu, Y. -L.
- [50] An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLCONCOGENE, 2019, 38 (09) : 1398 - 1409Yonesaka, KimioTakegawa, NaokiWatanabe, SatomiHaratani, KojiKawakami, HisatoSakai, KazukoChiba, YasutakaMaeda, NaoyukiKagari, TakashiHirotani, KenjiNishio, KazutoNakagawa, Kazuhiko